Transfusion Medicine (Oxford, England)最新文献

{"title":"Routine antenatal anti-D prophylaxis and patient compliance with the two-dose regimen.","authors":"B Chaffe,&nbsp;J Ford,&nbsp;V Bills","doi":"10.1111/j.1365-3148.2007.00777.x","DOIUrl":"https://doi.org/10.1111/j.1365-3148.2007.00777.x","url":null,"abstract":"<p><p>The aim of this study was to determine the compliance rates for women being offered routine antenatal anti-D prophylaxis in two obstetric units in the UK. Haemolytic disease of the newborn (HDN) is a potentially serious condition that can result in substantial morbidity and sometimes death. Current guidelines recommend that 500 IU anti-D immunoglobulin G (IgG) should be offered to all non-sensitized RhD-negative women at 28 and 34 weeks' gestation in order to prevent the risk of RhD sensitization in pregnancy. Implementing guidance, however, remains a challenge. We conducted a retrospective audit of 207 RhD-negative, non-sensitized pregnant women attending obstetric units during 2004 to assess compliance with national guidance on the provision of antenatal anti-D prophylaxis. Informed consent for routine antenatal anti-D prophylaxis was documented for 185 of these women. In total, 86.5% of women received the two doses of anti-D IgG. The majority of women received their first and second doses within 1 week of 28 and 34 weeks' gestation (87.0 and 86.0%, respectively). Accurate records of prophylactic anti-D IgG were maintained and updated. This audit demonstrates that the level of patient compliance with the two-dose regimen was high.</p>","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":" ","pages":"399-403"},"PeriodicalIF":1.5,"publicationDate":"2007-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1365-3148.2007.00777.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41001227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transfusion-transmitted malaria: how vital is the need to screen in non-endemic countries?","authors":"N Maalouf,&nbsp;M Naja,&nbsp;A R El Kinge,&nbsp;S Zein-El-Dine,&nbsp;A Taher","doi":"10.1111/j.1365-3148.2007.00780.x","DOIUrl":"https://doi.org/10.1111/j.1365-3148.2007.00780.x","url":null,"abstract":"American Association of Blood Banks, 2002, STAND BLOOD BANKS TR; Kitchen AD, 2006, VOX SANG, V90, P77, DOI 10.1111-j.1423-0410.2006.00733.x; Kitchen AD, 2005, VOX SANG, V89, P77, DOI 10.1111-j.1423-0410.2005.00661.x; Vento S, 2006, LANCET INFECT DIS, V6, P226, DOI 10.1016-S1473-3099(06)70437-6; Zoon K, 1994, RECOMMENDATIONS DEFE","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":" ","pages":"415-6"},"PeriodicalIF":1.5,"publicationDate":"2007-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1365-3148.2007.00780.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41001230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Studies in animal model on the thrombogenicity of a new prothrombin complex concentrate from Argentina.","authors":"M E Bernardi,&nbsp;M S Vitali,&nbsp;C Moya,&nbsp;H A Guglielmone,&nbsp;G R Cuadra","doi":"10.1111/j.1365-3148.2007.00775.x","DOIUrl":"https://doi.org/10.1111/j.1365-3148.2007.00775.x","url":null,"abstract":"Dear Sir Prothrombin complex concentrate (PCC) is a therapeutic agent human plasma derived that contains vitamin K-dependent coagulation factors (Roberts & Eberst, 1993). These may be manufactured as three factors (II, IXandX)or four factors (II, VII, IXandX), depending on the purification procedure (Chandra & Wickerhauser, 1978; Feldman & Winkelman, 1991). Furthermore, some concentrates have also variable quantities of protein Z and physiologic coagulation inhibitor proteins C and S (Romisch et al., 1998). PCC administration has been used in the treatment of hemophilia B, severe liver failure and consumption coagulopathies as well as in the therapy for the reversal of warfarin anticoagulation in emergency settings (Lankiewicz et al., 2006). However, the therapeutic use of PCC may be accompanied by adverse events, including allergic reactions, transmission of blood-borne viruses and thrombotic episodes (Watson & Ludlam, 1997). The thrombogenic components of these concentrates have been mainly attributed to activated coagulation factors and also to the presence of coagulant-active phospholipids, zymogen overload and the lack of inhibitors antithrombin and/or protein S (Kohler, 1999). To avoid the thrombotic complications of PCC, the International Society on Thrombosis and Haemostasis (ISTH) has recommended in the past the use of heparin in the formulation of the final product (Menache, 1976). However, strong evidences support that the quality of PCC plays a crucial role in the occurrence of thromboembolic events, whichmainly dependon the purification methods used during its manufacture (Kohler, 1999). As a consequence of these observations, we developed a PCC that meets the criteria of presumed low thrombogenicity because the content of vitamin K-dependent clotting factors and inhibitors is well balanced and the thrombin and activated factors activities were negligible by in vitro assays. This study was designed to evaluate a full-dose-related response for our PCC, using the in vivo stasis model of thrombogenicity (Wessler test), adapted to rats. Different lots (n 1⁄4 3) of PCC were studied and manufactured from human plasma at the Laboratorio de Hemoderivados, Universidad Nacional de Córdoba production facility (Córdoba, Argentina). The factors II, IX andXwere isolated from cryosupernatant using ion-exchange batch chromatography, and the coagulation factors were eluted using buffer of increased ionic strength. A first step of viral inactivation was performed with solvent–detergent and then a second chromatographic step was carried out. The proteins of interest were eluted, and the protein concentration was adjusted by ultrafiltration procedure and formulated with or without heparin. Finally, the PCC was aseptically distributed in a vial and lyophilized and a second step of viral inactivation using dryheat (100 C for 30 min) was applied (Bernardi et al., 2003). PCCs were standardized according to factor IX (F IX) activity, following the European P","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":" ","pages":"420-2"},"PeriodicalIF":1.5,"publicationDate":"2007-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1365-3148.2007.00775.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41001232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstracts of selected papers presented at the 39th Annual Scientific Meeting of the Australian and New Zealand Society of Blood Transfusion, Sydney Convention and Exhibition Centre, Darling Harbour, Sydney, Australia, 16–19 October 2005","authors":"","doi":"10.1111/j.1365-3148.2006.00660.x","DOIUrl":"https://doi.org/10.1111/j.1365-3148.2006.00660.x","url":null,"abstract":"s of selected papers presented at the 39 Annual Scientific Meeting of the Australian and New Zealand Society of Blood Transfusion, Sydney Convention and Exhibition Centre, Darling Harbour, Sydney, Australia,","PeriodicalId":442504,"journal":{"name":"Transfusion Medicine (Oxford, England)","volume":"194 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122387865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}